a trend toward significanceP = .06
The univariate analysis demonstrated a trend toward significance with pre-SABR chemotherapy for distant metastases (HR: 0.39; 95% CI, 0.15-1.04; P = .06) and 4 metastases versus 1 metastasis (HR: 8.91; 95% CI, 0.90-87.90; P = .06).